Recent News

• 11.03.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 11.02.2026 - Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
• 10.07.2026 - Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
• 09.21.2026 - Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
• 09.17.2026 - Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
• 09.02.2026 - Axsome Therapeutics to Participate in Upcoming Investor Conferences
• 08.31.2026 - Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
• 08.10.2026 - Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• 07.15.2026 - Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
• 07.14.2026 - Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

Recent Filings

• 11.02.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.02.2026 - 8-K Current report
• 11.02.2026 - EX-99.1 EX-99.1
• 09.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2026 - 144 Report of proposed sale of securities
• 08.10.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.10.2026 - 8-K Current report
• 08.10.2026 - EX-99.1 EX-99.1
• 08.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2026 - 144 Report of proposed sale of securities